• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

    3/9/21 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email

    LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors.

    “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice and insight will be instrumental to the Company’s development and growth.”

    Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries. She has served as Chief Financial Officer in both public and venture-backed private companies at all stages of development. Ms. Seymour’s experience includes leading finance, investor relations, managed care and reimbursement, human resources, administration and information technology. She has raised over $250 million in multiple private and public equity and debt financings, including spearheading an IPO.

    “Now is an exciting time to be joining Artelo as it considers multiple strategies to advance and accelerate its non-clinical and clinical stage programs,” added Ms. Seymour. “I look forward to working with the very capable team to realize even more of Artelo’s potential.”

    In addition to her experience as an officer in public companies, Ms. Seymour was also a member of the Board of Directors and Chair of the Audit Committee of Beacon Discovery, Inc., a drug discovery company in San Diego, California that was recently acquired by Eurofins Scientific. Ms. Seymour is a certified public accountant (inactive). She received an MBA, with an emphasis in finance, from Georgia State University and earned her BBA, with an emphasis in accounting, from Valdosta State University.

    About Artelo Biosciences

    Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

    Forward Looking Statements
    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

    Investor Relations Contact:
    Crescendo Communications, LLC
    Tel: 212-671-1020
    Email: [email protected]


    Get the next $ARTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/23/22 4:36:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/9/22 11:08:31 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/4/22 3:19:12 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

      11/1/21 6:29:39 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

      LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

      2/12/21 7:33:23 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Artelo Biosciences with a new price target

      Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00

      2/12/21 7:14:55 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

      SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025. Business Highlights: ART26.12: The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for the second quarter of 2025.Newly published peer-reviewed

      5/13/25 8:00:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

      SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK. In the course of the presentation, titled "Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications," Mr. Osborn will discuss an analysis of multiple datasets across

      3/31/25 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

      SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024. Business Highlights: ART26.12: Phase I study is on track for completion in Q2 2025.ART27.13: Initial data from the Phase 2 CAReS trial anticipated by the end of Q2 2025.ART12.11: Substantial progress has been made toward initiation of human studies with an oral solid dosage form

      3/3/25 8:00:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    SEC Filings

    See more
    • Artelo Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/23/25 4:30:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Artelo Biosciences Inc.

      10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/13/25 8:22:40 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/1/25 4:24:33 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

      SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

      5/4/21 8:00:00 AM ET
      $KTRA
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

      LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

      3/9/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

      LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem

      2/16/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Favorito Tamara A

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:24:07 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Matsui Connie

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:52 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pres, CEO, CFO, Treas & Secr Gorgas Gregory D.

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care